Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALDOCLOR-250 vs PRECOSE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Off-label: Prevention of type 2 diabetes in patients with impaired glucose tolerance
250 mg orally twice daily
Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Terminal elimination half-life is approximately 2 hours for the parent drug, but clinical effect persists due to prolonged binding to intestinal alpha-glucosidases.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Not extensively metabolized; primarily excreted unchanged in the urine as active drug. Small fraction undergoes intestinal metabolism by digestive enzymes.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Primarily excreted in feces (about 85%) as unchanged drug and metabolites, with less than 2% excreted renally as active metabolites.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Low protein binding, approximately 5%, primarily to albumin.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Volume of distribution is approximately 0.3 L/kg, indicating minimal distribution into tissues and predominantly confined to extracellular fluid.
70-90% (oral); 100% (IV).
Oral bioavailability is low, approximately 2%, due to local action in the gastrointestinal tract and minimal systemic absorption.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <25 m L/min/1.73 m²).
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
No dose adjustment recommended for mild hepatic impairment. Not studied in moderate to severe hepatic impairment (Child-Pugh B or C); avoid use.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Not recommended for pediatric patients (safety and efficacy not established).
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No specific dose adjustment required; monitor renal function due to age-related decline. Start at low end of dosing range (25 mg three times daily).
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
None.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypoglycemia: Acarbose does not cause hypoglycemia when used alone, but may increase risk when combined with sulfonylureas or insulin. Hypoglycemic episodes should be treated with glucose (dextrose), not sucrose.,Hepatic injury: Rare cases of acute hepatitis, jaundice, and fulminant hepatic failure; monitor liver function tests.,Renal impairment: Contraindicated in patients with Cr Cl <25 m L/min.,Gastrointestinal effects: Frequently causes flatulence, diarrhea, and abdominal discomfort due to undigested carbohydrates; these effects may diminish with continued use.
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Hypersensitivity to acarbose or any component,Diabetic ketoacidosis,Cirrhosis,Inflammatory bowel disease,Colonic ulceration,Partial intestinal obstruction or predisposition to intestinal obstruction,Chronic intestinal diseases associated with marked disorders of digestion or absorption,Conditions that may deteriorate as a result of increased intestinal gas formation (e.g., Roemheld syndrome),Severe renal impairment (Cr Cl <25 m L/min)
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Avoid sucrose and table sugar as they may worsen GI side effects. Dietary carbohydrates increase efficacy but also GI side effects. Precose alone does not cause hypoglycemia; however, if used with insulin or sulfonylureas, hypoglycemia must be treated with glucose (dextrose) because absorption of complex sugars and sucrose is inhibited.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Unknown if excreted in human milk. Caution advised. M/P ratio not established.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
No dose adjustment recommended; monitor glucose control closely as pharmacokinetics may change; insulin often preferred.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Precose (acarbose) is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is most effective for postprandial hyperglycemia. Must be taken with the first bite of each main meal. Avoid use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Can cause elevated liver enzymes; monitor LFTs every 3 months during first year. Hypoglycemia from other agents should be treated with glucose (not sucrose) because sucrase is inhibited.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
Take this medication with the first bite of each main meal.,If you experience low blood sugar, treat it with glucose tablets or milk, not fruit juice or regular soda.,Common side effects include flatulence, diarrhea, and abdominal pain, which often decrease with time.,Do not take this drug if you have severe kidney problems or certain bowel diseases.,Report any signs of liver problems (yellow skin/eyes, dark urine, abdominal pain) immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALDOCLOR-250 vs PRECOSE, answered by our medical review team.
ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. PRECOSE is a Alpha-Glucosidase Inhibitor Antidiabetic that works by Alpha-glucosidase inhibitor; competitively inhibits brush-border alpha-glucosidases in the small intestine, delaying carbohydrate digestion and reducing postprandial hyperglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALDOCLOR-250 and PRECOSE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. The standard adult dose of PRECOSE is: Initial: 25 mg orally three times daily with the first bite of each main meal; maintenance: 50-100 mg three times daily; maximum 100 mg three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALDOCLOR-250 and PRECOSE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. PRECOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies at doses up to 200 mg/kg/day (6-15 times human exposure). No adequate human studies; risk cannot be ruled out.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.